ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Myriad Genetics Dl 01

Myriad Genetics Dl 01 (0K3W)

35,68
0,00
(0,00%)
Geschlossen 06 Juli 5:30PM

Myriad Genetics Dl 01 (0K3W) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
35,68
( - )
Gebot
35,68
Fragen
35,68
Volumen
0,00
0,00 Tagesbereich 0,00
35,68 52-Wochen-Bereich 35,68
Marktkapitalisierung
Handelsende
35,68
Handelsbeginn
-
Letzte Trade
(O)
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 1.630.263
Ausgegebene Aktien
94.448.210
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-1,4
Gewinn pro Aktie (EPS)
-4,29
Erlöse (LTM)
829M
Nettogewinn (LTM)
-399,9M

Über Myriad Genetics Dl 01

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRA... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Mehr anzeigen

Sektor
-
Branche
-
Website
Hauptsitz
Salt Lake City, United States
Gegründet
1991
Myriad Genetics Dl 01 is listed in the sector of the Londoner Börse with ticker 0K3W. The last closing price for Myriad Genetics Dl 01 was US$35,68. Over the last year, Myriad Genetics Dl 01 shares have traded in a share price range of US$ 35,68 to US$ 35,68.

Myriad Genetics Dl 01 currently has 94.448.210 shares in issue. The market capitalisation of Myriad Genetics Dl 01 is US$3,37 billion. Myriad Genetics Dl 01 has a price to earnings ratio (PE ratio) of -1.40.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DE
40000000DE
120000000DE
260035.6835.6835.68222835.68DE
520035.6835.6835.68332035.68DE
1560035.6835.6835.68124435.68DE
2600035.6835.6835.6873835.68DE

0K3W - Frequently Asked Questions (FAQ)

What is the current Myriad Genetics Dl 01 share price?
The current share price of Myriad Genetics Dl 01 is US$ 35,68
How many Myriad Genetics Dl 01 shares are in issue?
Myriad Genetics Dl 01 has 94.448.210 shares in issue
What is the market cap of Myriad Genetics Dl 01?
The market capitalisation of Myriad Genetics Dl 01 is USD 3,37B
What is the 1 year trading range for Myriad Genetics Dl 01 share price?
Myriad Genetics Dl 01 has traded in the range of US$ 35,68 to US$ 35,68 during the past year
What is the PE ratio of Myriad Genetics Dl 01?
The price to earnings ratio of Myriad Genetics Dl 01 is -1,4
What is the cash to sales ratio of Myriad Genetics Dl 01?
The cash to sales ratio of Myriad Genetics Dl 01 is 0,68
What is the registered address of Myriad Genetics Dl 01?
The registered address for Myriad Genetics Dl 01 is 322 North 2200 West, Salt Lake City, Utah, 84116
What is the Myriad Genetics Dl 01 website address?
The website address for Myriad Genetics Dl 01 is www.myriad.com

0K3W Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen